Second consensus statement on the diagnosis of multiple system atrophy
Identifieur interne : 000302 ( Pmc/Corpus ); précédent : 000301; suivant : 000303Second consensus statement on the diagnosis of multiple system atrophy
Auteurs : S. Gilman ; G K. Wenning ; P A. Low ; D J. Brooks ; C J. Mathias ; J Q. Trojanowski ; N W. Wood ; C. Colosimo ; A. Dürr ; C J. Fowler ; H. Kaufmann ; T. Klockgether ; A. Lees ; W. Poewe ; N. Quinn ; T. Revesz ; D. Robertson ; P. Sandroni ; K. Seppi ; M. VidailhetSource :
- Neurology [ 0028-3878 ] ; 2008.
Abstract
A consensus conference on multiple system atrophy (MSA) in 1998 established criteria for diagnosis that have been accepted widely. Since then, clinical, laboratory, neuropathologic, and imaging studies have advanced the field, requiring a fresh evaluation of diagnostic criteria. We held a second consensus conference in 2007 and present the results here.
Experts in the clinical, neuropathologic, and imaging aspects of MSA were invited to participate in a 2-day consensus conference. Participants were divided into five groups, consisting of specialists in the parkinsonian, cerebellar, autonomic, neuropathologic, and imaging aspects of the disorder. Each group independently wrote diagnostic criteria for its area of expertise in advance of the meeting. These criteria were discussed and reconciled during the meeting using consensus methodology.
The new criteria retain the diagnostic categories of MSA with predominant parkinsonism and MSA with predominant cerebellar ataxia to designate the predominant motor features and also retain the designations of definite, probable, and possible MSA. Definite MSA requires neuropathologic demonstration of CNS α-synuclein–positive glial cytoplasmic inclusions with neurodegenerative changes in striatonigral or olivopontocerebellar structures. Probable MSA requires a sporadic, progressive adult-onset disorder including rigorously defined autonomic failure and poorly levodopa-responsive parkinsonism or cerebellar ataxia. Possible MSA requires a sporadic, progressive adult-onset disease including parkinsonism or cerebellar ataxia and at least one feature suggesting autonomic dysfunction plus one other feature that may be a clinical or a neuroimaging abnormality.
These new criteria have simplified the previous criteria, have incorporated current knowledge, and are expected to enhance future assessments of the disease.
= [11C]hydroxyephedrine;
= American Academy of Neurology;
= American Autonomic Society;
=
= diffusion-weighted imaging;
= erectile dysfunction;
= [18F]fluorodeoxyglucose;
= fragile X–associated tremor/ataxia syndrome;
= middle cerebellar peduncle;
= [123I]metaiodobenzylguanidine;
= magnetic resonance;
= multiple system atrophy;
= MSA with predominant cerebellar ataxia;
= MSA with predominant parkinsonism;
= orthostatic hypotension;
= Parkinson disease;
= spinocerebellar ataxia;
= Safety Monitoring Committee;
= residual volume;
= Unified Parkinson's Disease Rating Scale.
Url:
DOI: 10.1212/01.wnl.0000324625.00404.15
PubMed: 18725592
PubMed Central: 2676993
Links to Exploration step
PMC:2676993Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Second consensus statement on the diagnosis of multiple system atrophy</title><author><name sortKey="Gilman, S" sort="Gilman, S" uniqKey="Gilman S" first="S" last="Gilman">S. Gilman</name></author><author><name sortKey="Wenning, G K" sort="Wenning, G K" uniqKey="Wenning G" first="G K." last="Wenning">G K. Wenning</name></author><author><name sortKey="Low, P A" sort="Low, P A" uniqKey="Low P" first="P A." last="Low">P A. Low</name></author><author><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D J." last="Brooks">D J. Brooks</name></author><author><name sortKey="Mathias, C J" sort="Mathias, C J" uniqKey="Mathias C" first="C J." last="Mathias">C J. Mathias</name></author><author><name sortKey="Trojanowski, J Q" sort="Trojanowski, J Q" uniqKey="Trojanowski J" first="J Q." last="Trojanowski">J Q. Trojanowski</name></author><author><name sortKey="Wood, N W" sort="Wood, N W" uniqKey="Wood N" first="N W." last="Wood">N W. Wood</name></author><author><name sortKey="Colosimo, C" sort="Colosimo, C" uniqKey="Colosimo C" first="C" last="Colosimo">C. Colosimo</name></author><author><name sortKey="Durr, A" sort="Durr, A" uniqKey="Durr A" first="A" last="Dürr">A. Dürr</name></author><author><name sortKey="Fowler, C J" sort="Fowler, C J" uniqKey="Fowler C" first="C J." last="Fowler">C J. Fowler</name></author><author><name sortKey="Kaufmann, H" sort="Kaufmann, H" uniqKey="Kaufmann H" first="H" last="Kaufmann">H. Kaufmann</name></author><author><name sortKey="Klockgether, T" sort="Klockgether, T" uniqKey="Klockgether T" first="T" last="Klockgether">T. Klockgether</name></author><author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A" last="Lees">A. Lees</name></author><author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W" last="Poewe">W. Poewe</name></author><author><name sortKey="Quinn, N" sort="Quinn, N" uniqKey="Quinn N" first="N" last="Quinn">N. Quinn</name></author><author><name sortKey="Revesz, T" sort="Revesz, T" uniqKey="Revesz T" first="T" last="Revesz">T. Revesz</name></author><author><name sortKey="Robertson, D" sort="Robertson, D" uniqKey="Robertson D" first="D" last="Robertson">D. Robertson</name></author><author><name sortKey="Sandroni, P" sort="Sandroni, P" uniqKey="Sandroni P" first="P" last="Sandroni">P. Sandroni</name></author><author><name sortKey="Seppi, K" sort="Seppi, K" uniqKey="Seppi K" first="K" last="Seppi">K. Seppi</name></author><author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M" last="Vidailhet">M. Vidailhet</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">18725592</idno><idno type="pmc">2676993</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676993</idno><idno type="RBID">PMC:2676993</idno><idno type="doi">10.1212/01.wnl.0000324625.00404.15</idno><date when="2008">2008</date><idno type="wicri:Area/Pmc/Corpus">000302</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000302</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Second consensus statement on the diagnosis of multiple system atrophy</title><author><name sortKey="Gilman, S" sort="Gilman, S" uniqKey="Gilman S" first="S" last="Gilman">S. Gilman</name></author><author><name sortKey="Wenning, G K" sort="Wenning, G K" uniqKey="Wenning G" first="G K." last="Wenning">G K. Wenning</name></author><author><name sortKey="Low, P A" sort="Low, P A" uniqKey="Low P" first="P A." last="Low">P A. Low</name></author><author><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D J." last="Brooks">D J. Brooks</name></author><author><name sortKey="Mathias, C J" sort="Mathias, C J" uniqKey="Mathias C" first="C J." last="Mathias">C J. Mathias</name></author><author><name sortKey="Trojanowski, J Q" sort="Trojanowski, J Q" uniqKey="Trojanowski J" first="J Q." last="Trojanowski">J Q. Trojanowski</name></author><author><name sortKey="Wood, N W" sort="Wood, N W" uniqKey="Wood N" first="N W." last="Wood">N W. Wood</name></author><author><name sortKey="Colosimo, C" sort="Colosimo, C" uniqKey="Colosimo C" first="C" last="Colosimo">C. Colosimo</name></author><author><name sortKey="Durr, A" sort="Durr, A" uniqKey="Durr A" first="A" last="Dürr">A. Dürr</name></author><author><name sortKey="Fowler, C J" sort="Fowler, C J" uniqKey="Fowler C" first="C J." last="Fowler">C J. Fowler</name></author><author><name sortKey="Kaufmann, H" sort="Kaufmann, H" uniqKey="Kaufmann H" first="H" last="Kaufmann">H. Kaufmann</name></author><author><name sortKey="Klockgether, T" sort="Klockgether, T" uniqKey="Klockgether T" first="T" last="Klockgether">T. Klockgether</name></author><author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A" last="Lees">A. Lees</name></author><author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W" last="Poewe">W. Poewe</name></author><author><name sortKey="Quinn, N" sort="Quinn, N" uniqKey="Quinn N" first="N" last="Quinn">N. Quinn</name></author><author><name sortKey="Revesz, T" sort="Revesz, T" uniqKey="Revesz T" first="T" last="Revesz">T. Revesz</name></author><author><name sortKey="Robertson, D" sort="Robertson, D" uniqKey="Robertson D" first="D" last="Robertson">D. Robertson</name></author><author><name sortKey="Sandroni, P" sort="Sandroni, P" uniqKey="Sandroni P" first="P" last="Sandroni">P. Sandroni</name></author><author><name sortKey="Seppi, K" sort="Seppi, K" uniqKey="Seppi K" first="K" last="Seppi">K. Seppi</name></author><author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M" last="Vidailhet">M. Vidailhet</name></author></analytic><series><title level="j">Neurology</title><idno type="ISSN">0028-3878</idno><idno type="eISSN">1526-632X</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background:</title><p>A consensus conference on multiple system atrophy (MSA) in 1998 established criteria for diagnosis that have been accepted widely. Since then, clinical, laboratory, neuropathologic, and imaging studies have advanced the field, requiring a fresh evaluation of diagnostic criteria. We held a second consensus conference in 2007 and present the results here.</p></sec><sec><title>Methods:</title><p>Experts in the clinical, neuropathologic, and imaging aspects of MSA were invited to participate in a 2-day consensus conference. Participants were divided into five groups, consisting of specialists in the parkinsonian, cerebellar, autonomic, neuropathologic, and imaging aspects of the disorder. Each group independently wrote diagnostic criteria for its area of expertise in advance of the meeting. These criteria were discussed and reconciled during the meeting using consensus methodology.</p></sec><sec><title>Results:</title><p>The new criteria retain the diagnostic categories of MSA with predominant parkinsonism and MSA with predominant cerebellar ataxia to designate the predominant motor features and also retain the designations of definite, probable, and possible MSA. Definite MSA requires neuropathologic demonstration of CNS α-synuclein–positive glial cytoplasmic inclusions with neurodegenerative changes in striatonigral or olivopontocerebellar structures. Probable MSA requires a sporadic, progressive adult-onset disorder including rigorously defined autonomic failure and poorly levodopa-responsive parkinsonism or cerebellar ataxia. Possible MSA requires a sporadic, progressive adult-onset disease including parkinsonism or cerebellar ataxia and at least one feature suggesting autonomic dysfunction plus one other feature that may be a clinical or a neuroimaging abnormality.</p></sec><sec><title>Conclusions:</title><p>These new criteria have simplified the previous criteria, have incorporated current knowledge, and are expected to enhance future assessments of the disease.</p></sec><sec><title>GLOSSARY</title><def-list list-type="abr"><def-item><term><bold>[<sup>11</sup>C]HED</bold></term><def><p> = [<sup>11</sup>C]hydroxyephedrine; </p></def></def-item><def-item><term><bold>AAN</bold></term><def><p> = American Academy of Neurology; </p></def></def-item><def-item><term><bold>AAS</bold></term><def><p> = American Autonomic Society; </p></def></def-item><def-item><term><bold>DSM-IV</bold></term><def><p> = <italic>Diagnostic and Statistical Manual of Mental Disorders</italic>, Fourth Edition; </p></def></def-item><def-item><term><bold>DWI</bold></term><def><p> = diffusion-weighted imaging; </p></def></def-item><def-item><term><bold>ED</bold></term><def><p> = erectile dysfunction; </p></def></def-item><def-item><term><bold>FDG</bold></term><def><p> = [<sup>18</sup>F]fluorodeoxyglucose; </p></def></def-item><def-item><term><bold>FXTAS</bold></term><def><p> = fragile X–associated tremor/ataxia syndrome; </p></def></def-item><def-item><term><bold>MCP</bold></term><def><p> = middle cerebellar peduncle; </p></def></def-item><def-item><term><bold>MIBG</bold></term><def><p> = [<sup>123</sup>I]metaiodobenzylguanidine; </p></def></def-item><def-item><term><bold>MR</bold></term><def><p> = magnetic resonance; </p></def></def-item><def-item><term><bold>MSA</bold></term><def><p> = multiple system atrophy; </p></def></def-item><def-item><term><bold>MSA-C</bold></term><def><p> = MSA with predominant cerebellar ataxia; </p></def></def-item><def-item><term><bold>MSA-P</bold></term><def><p> = MSA with predominant parkinsonism; </p></def></def-item><def-item><term><bold>OH</bold></term><def><p> = orthostatic hypotension; </p></def></def-item><def-item><term><bold>PD</bold></term><def><p> = Parkinson disease; </p></def></def-item><def-item><term><bold>SCA</bold></term><def><p> = spinocerebellar ataxia; </p></def></def-item><def-item><term><bold>SMC</bold></term><def><p> = Safety Monitoring Committee; </p></def></def-item><def-item><term><bold>RV</bold></term><def><p> = residual volume; </p></def></def-item><def-item><term><bold>UPDRS</bold></term><def><p> = Unified Parkinson's Disease Rating Scale.</p></def></def-item></def-list></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-title>Neurology</journal-title><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>American Academy of Neurology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18725592</article-id><article-id pub-id-type="pmc">2676993</article-id><article-id pub-id-type="publisher-id">znl03308000670</article-id><article-id pub-id-type="doi">10.1212/01.wnl.0000324625.00404.15</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Second consensus statement on the diagnosis of multiple system atrophy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gilman</surname><given-names>S</given-names></name><degrees>MD, FRCP</degrees></contrib><contrib contrib-type="author"><name><surname>Wenning</surname><given-names>G K.</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Low</surname><given-names>P A.</given-names></name><degrees>MD, FRACP, FRCP(Hon)</degrees></contrib><contrib contrib-type="author"><name><surname>Brooks</surname><given-names>D J.</given-names></name><degrees>MD, DSc, FRCP, FMedSci</degrees></contrib><contrib contrib-type="author"><name><surname>Mathias</surname><given-names>C J.</given-names></name><degrees>MBBS, DPhil, DSc, FRCP, FMedSci</degrees></contrib><contrib contrib-type="author"><name><surname>Trojanowski</surname><given-names>J Q.</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Wood</surname><given-names>N W.</given-names></name><degrees>MB, ChB, PhD, FRCP</degrees></contrib><contrib contrib-type="author"><name><surname>Colosimo</surname><given-names>C</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Dürr</surname><given-names>A</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Fowler</surname><given-names>C J.</given-names></name><degrees>FRCP</degrees></contrib><contrib contrib-type="author"><name><surname>Kaufmann</surname><given-names>H</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Klockgether</surname><given-names>T</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Lees</surname><given-names>A</given-names></name><degrees>MD, FRCP</degrees></contrib><contrib contrib-type="author"><name><surname>Poewe</surname><given-names>W</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Quinn</surname><given-names>N</given-names></name><degrees>MD, FRCP</degrees></contrib><contrib contrib-type="author"><name><surname>Revesz</surname><given-names>T</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Robertson</surname><given-names>D</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Sandroni</surname><given-names>P</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Seppi</surname><given-names>K</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Vidailhet</surname><given-names>M</given-names></name><degrees>MD, PhD</degrees></contrib></contrib-group><aff><bold>AFFILIATIONS</bold> From the Departments of Neurology, University of Michigan (S.G.), Ann Arbor, MI; Medical University of Innsbruck (G.K.W., W.P., K.S.), Austria; Mayo Clinic Rochester (P.A.L., P.S), Minnesota; and University Hospital Bonn (T.K.), Germany; Hammersmith Hospital and Department of Clinical Neuroscience (D.B.), Imperial College London, UK; Neurovascular Medicine (Pickering) Unit Faculty of Medicine (C.J.M.), Imperial College London, UK; Department of Pathology and Laboratory Medicine (J.Q.T.), University of Pennsylvania, Philadelphia, PA; National Hospital Queen Square (N.W.W., C.F., A.L., N.Q., T.R.), London, UK; Department of Neurological Sciences (C.C.), University of Rome La Sapienza, Italy; INSERM U289 Hôpital de la Salpêtrière (A.D.), Paris, France; New York University School of Medicine (H.K.), New York, NY; Vanderbilt University Clinical Research Center (D.R.), Nashville, TN; and Federation of Neurology and INSERM U679 (M.V.), Pierre Marie Curie Paris-6 University, France.<break></break></aff><pub-date pub-type="ppub"><day>26</day><month>8</month><year>2008</year></pub-date><volume>71</volume><issue>9</issue><fpage>670</fpage><lpage>676</lpage><copyright-statement>Copyright © 2008 by AAN Enterprises, Inc.</copyright-statement><abstract><sec><title>Background:</title><p>A consensus conference on multiple system atrophy (MSA) in 1998 established criteria for diagnosis that have been accepted widely. Since then, clinical, laboratory, neuropathologic, and imaging studies have advanced the field, requiring a fresh evaluation of diagnostic criteria. We held a second consensus conference in 2007 and present the results here.</p></sec><sec><title>Methods:</title><p>Experts in the clinical, neuropathologic, and imaging aspects of MSA were invited to participate in a 2-day consensus conference. Participants were divided into five groups, consisting of specialists in the parkinsonian, cerebellar, autonomic, neuropathologic, and imaging aspects of the disorder. Each group independently wrote diagnostic criteria for its area of expertise in advance of the meeting. These criteria were discussed and reconciled during the meeting using consensus methodology.</p></sec><sec><title>Results:</title><p>The new criteria retain the diagnostic categories of MSA with predominant parkinsonism and MSA with predominant cerebellar ataxia to designate the predominant motor features and also retain the designations of definite, probable, and possible MSA. Definite MSA requires neuropathologic demonstration of CNS α-synuclein–positive glial cytoplasmic inclusions with neurodegenerative changes in striatonigral or olivopontocerebellar structures. Probable MSA requires a sporadic, progressive adult-onset disorder including rigorously defined autonomic failure and poorly levodopa-responsive parkinsonism or cerebellar ataxia. Possible MSA requires a sporadic, progressive adult-onset disease including parkinsonism or cerebellar ataxia and at least one feature suggesting autonomic dysfunction plus one other feature that may be a clinical or a neuroimaging abnormality.</p></sec><sec><title>Conclusions:</title><p>These new criteria have simplified the previous criteria, have incorporated current knowledge, and are expected to enhance future assessments of the disease.</p></sec><sec><title>GLOSSARY</title><def-list list-type="abr"><def-item><term><bold>[<sup>11</sup>C]HED</bold></term><def><p> = [<sup>11</sup>C]hydroxyephedrine; </p></def></def-item><def-item><term><bold>AAN</bold></term><def><p> = American Academy of Neurology; </p></def></def-item><def-item><term><bold>AAS</bold></term><def><p> = American Autonomic Society; </p></def></def-item><def-item><term><bold>DSM-IV</bold></term><def><p> = <italic>Diagnostic and Statistical Manual of Mental Disorders</italic>, Fourth Edition; </p></def></def-item><def-item><term><bold>DWI</bold></term><def><p> = diffusion-weighted imaging; </p></def></def-item><def-item><term><bold>ED</bold></term><def><p> = erectile dysfunction; </p></def></def-item><def-item><term><bold>FDG</bold></term><def><p> = [<sup>18</sup>F]fluorodeoxyglucose; </p></def></def-item><def-item><term><bold>FXTAS</bold></term><def><p> = fragile X–associated tremor/ataxia syndrome; </p></def></def-item><def-item><term><bold>MCP</bold></term><def><p> = middle cerebellar peduncle; </p></def></def-item><def-item><term><bold>MIBG</bold></term><def><p> = [<sup>123</sup>I]metaiodobenzylguanidine; </p></def></def-item><def-item><term><bold>MR</bold></term><def><p> = magnetic resonance; </p></def></def-item><def-item><term><bold>MSA</bold></term><def><p> = multiple system atrophy; </p></def></def-item><def-item><term><bold>MSA-C</bold></term><def><p> = MSA with predominant cerebellar ataxia; </p></def></def-item><def-item><term><bold>MSA-P</bold></term><def><p> = MSA with predominant parkinsonism; </p></def></def-item><def-item><term><bold>OH</bold></term><def><p> = orthostatic hypotension; </p></def></def-item><def-item><term><bold>PD</bold></term><def><p> = Parkinson disease; </p></def></def-item><def-item><term><bold>SCA</bold></term><def><p> = spinocerebellar ataxia; </p></def></def-item><def-item><term><bold>SMC</bold></term><def><p> = Safety Monitoring Committee; </p></def></def-item><def-item><term><bold>RV</bold></term><def><p> = residual volume; </p></def></def-item><def-item><term><bold>UPDRS</bold></term><def><p> = Unified Parkinson's Disease Rating Scale.</p></def></def-item></def-list></sec></abstract></article-meta><notes><p>Address correspondence and reprint requests to Dr. Sid Gilman, Department of Neurology, University of Michigan, 300 N. Ingalls St., 3D15, Ann Arbor, MI 48109-5489 <email>sgilman@umich.edu</email></p><p>Author's affiliations are listed at the end of the article.</p><p>Supported in part by grants from the NIH (National Institute of Neurological Disorders and Stroke grant 1 R13 NS055459), Novartis Pharmaceuticals, and Chelsea Therapeutics.</p><p><italic>Disclosure:</italic> Author disclosures are provided at the end of the article.</p><p>Received January 4, 2008. Accepted in final form May 23, 2008.</p></notes></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000302 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000302 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:2676993
|texte= Second consensus statement on the diagnosis of multiple system atrophy
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:18725592" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |